Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement
Taha Hatab, Syed Zaid, Priscilla Wessly, Nadeen Faza, Stephen H. Little, Marvin D. Atkins, Michael J. Reardon, Neal S. Kleiman, William A. Zoghbi, Sachin S. Goel
Abstract
Mitral transcatheter edge-to-edge repair (TEER) has proven to be a safe and effective treatment option in patients with primary mitral regurgitation (MR) at high or prohibitive surgical risk or those with secondary MR who remain symptomatic despite guideline-directed medical therapy (GDMT) and have favorable anatomy.1 Transcatheter mitral valve replacement (TMVR) is emerging as an important therapy for patients with symptomatic severe primary or secondary MR who are deemed high surgical risk and have unfavorable anatomy for TEER.
Topics & Concepts
Mitral regurgitationMedicineMitral valve replacementMitral valveMedical therapyGuidelineValve replacementCardiologySurgeryFunctional mitral regurgitationInternal medicineHeart failureEjection fractionPathologyStenosisCardiac Valve Diseases and TreatmentsInfective Endocarditis Diagnosis and ManagementCardiac pacing and defibrillation studies